IL124442A0 - Methods of increasing lean tissue mass using ob protein compositions - Google Patents

Methods of increasing lean tissue mass using ob protein compositions

Info

Publication number
IL124442A0
IL124442A0 IL12444296A IL12444296A IL124442A0 IL 124442 A0 IL124442 A0 IL 124442A0 IL 12444296 A IL12444296 A IL 12444296A IL 12444296 A IL12444296 A IL 12444296A IL 124442 A0 IL124442 A0 IL 124442A0
Authority
IL
Israel
Prior art keywords
methods
protein compositions
tissue mass
lean tissue
increasing lean
Prior art date
Application number
IL12444296A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL124442A0 publication Critical patent/IL124442A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12444296A 1995-11-22 1996-11-04 Methods of increasing lean tissue mass using ob protein compositions IL124442A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56173295A 1995-11-22 1995-11-22
PCT/US1996/017718 WO1997018833A1 (fr) 1995-11-22 1996-11-04 Procedes permettant d'accroitre la masse tissulaire maigre a l'aide de compositions a base de proteine ob

Publications (1)

Publication Number Publication Date
IL124442A0 true IL124442A0 (en) 1998-12-06

Family

ID=24243198

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12444296A IL124442A0 (en) 1995-11-22 1996-11-04 Methods of increasing lean tissue mass using ob protein compositions
IL127926A IL127926A (en) 1995-11-22 1999-01-05 Fusion protein comprising all, or a portion, of an antibody constant portion, of an antibody constant region, attached to the n-terminus of a human ob protein

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL127926A IL127926A (en) 1995-11-22 1999-01-05 Fusion protein comprising all, or a portion, of an antibody constant portion, of an antibody constant region, attached to the n-terminus of a human ob protein

Country Status (15)

Country Link
EP (3) EP1285664B1 (fr)
JP (2) JP4173914B2 (fr)
AT (2) ATE259243T1 (fr)
AU (3) AU7607496A (fr)
CA (2) CA2236163A1 (fr)
DE (2) DE69631544T2 (fr)
DK (1) DK0866720T3 (fr)
ES (2) ES2339846T3 (fr)
IL (2) IL124442A0 (fr)
MX (1) MX9803992A (fr)
NZ (3) NZ512083A (fr)
PT (1) PT866720E (fr)
SI (1) SI0866720T1 (fr)
WO (1) WO1997018833A1 (fr)
ZA (1) ZA969605B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
NZ512083A (en) * 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US5831017A (en) * 1996-01-25 1998-11-03 Eli Lilly And Company Obesity protein analog compounds and formulations thereof
JP2000509377A (ja) * 1996-04-19 2000-07-25 ザイモジェネティクス，インコーポレイティド 骨形成を誘発するための方法
EP1007648A4 (fr) * 1996-12-20 2003-01-15 Lilly Co Eli Proteines anti-obesite
PT954588E (pt) * 1996-12-20 2007-03-30 Amgen Inc Composições que contêm uma proteína de fusão ob e métodos para a sua preparação e utilização
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
EP0950417A3 (fr) 1998-02-23 2000-02-23 Pfizer Products Inc. Traitement d' anomalies du squelette
AU3863699A (en) * 1998-04-20 1999-11-08 Mayo Foundation For Medical Education And Research Treatment of osteoporosis with leptin
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
WO2000024418A1 (fr) * 1998-10-27 2000-05-04 Eli Lilly And Company Prevention de la perte de masse musculaire au moyen de ligands du recepteur de la leptine
EP1151102B1 (fr) * 1999-02-12 2006-04-19 Amgen Inc. Compositions glycosylees de leptine et procedes correspondants
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
DE60237100D1 (de) 2001-10-22 2010-09-02 Amgen Inc Verwendung von leptin zur behandlung von lipoatropr prädisposition gegenüber der behandlung
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
WO2006005058A2 (fr) * 2004-06-30 2006-01-12 Nektar Therapeutics Al, Corporation Conjugues polymere-fraction facteur ix
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
EP2286837A3 (fr) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Traitement de l'obésité et de maladies liés à l'obésité
WO2008048691A2 (fr) * 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Utilisation de leptine pour le traitement de dépôt de graisse ectopique après une lipectomie et d'autres troubles associés après une lipectomie
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
BR122021020041B1 (pt) 2010-09-28 2023-03-07 Amylin Pharmaceuticals, Llc Polipeptídeo quimérico, seu uso e composição que o compreende
LT2900230T (lt) 2012-09-27 2019-01-10 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
CA2931826C (fr) 2013-11-26 2021-11-16 The Children's Medical Center Corporation Composes pour le traitement de l'obesite et leurs procedes d'utilisation
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
EP3509624B1 (fr) 2016-09-12 2023-08-09 Amryt Pharmaceuticals Inc. Procédés de détection d'anticorps neutralisants anti-leptine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1228925B (it) * 1987-08-07 1991-07-10 Eniricerche Spa Procedimento per la preparazione dell'ormone della crescita umano
DK173142B1 (da) * 1988-08-24 2000-02-07 Natinco Nv Fremgangsmåde til forbedring af kødkvaliteten og foderomsætningseffektiviteten for grise
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
DE4428146A1 (de) * 1993-08-13 1995-02-16 Putzmeister Maschf Verfahren und Anordnung zur Oberflächenbearbeitung von Großobjekten
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
NZ512083A (en) * 1995-11-22 2003-02-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
JP4037905B2 (ja) * 1995-12-27 2008-01-23 ジェネンテック・インコーポレーテッド 半減期の長いｏｂタンパク質誘導体
PT954588E (pt) * 1996-12-20 2007-03-30 Amgen Inc Composições que contêm uma proteína de fusão ob e métodos para a sua preparação e utilização
AU7132798A (en) * 1997-04-17 1998-11-11 Amgen, Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods

Also Published As

Publication number Publication date
EP0956862A1 (fr) 1999-11-17
IL127926A0 (en) 1999-11-30
WO1997018833A1 (fr) 1997-05-29
AU7607496A (en) 1997-06-11
ES2339846T3 (es) 2010-05-26
CA2358862A1 (fr) 1997-05-29
NZ512083A (en) 2003-02-28
EP1285664A2 (fr) 2003-02-26
EP0866720A1 (fr) 1998-09-30
AU763769B2 (en) 2003-07-31
NZ511617A (en) 2003-08-29
AU763755B2 (en) 2003-07-31
JP4227325B2 (ja) 2009-02-18
JP2000500492A (ja) 2000-01-18
CA2236163A1 (fr) 1997-05-29
JP2002206000A (ja) 2002-07-23
ES2217327T3 (es) 2004-11-01
SI0866720T1 (en) 2004-10-31
JP4173914B2 (ja) 2008-10-29
EP1285664A3 (fr) 2003-07-30
IL127926A (en) 2006-08-20
AU4265300A (en) 2000-09-07
DK0866720T3 (da) 2004-06-14
EP0866720B1 (fr) 2004-02-11
PT866720E (pt) 2004-06-30
EP1285664B1 (fr) 2010-01-20
DE69631544D1 (de) 2004-03-18
ZA969605B (en) 1997-06-02
DE69638119D1 (de) 2010-03-11
NZ527007A (en) 2005-01-28
AU4265200A (en) 2000-09-21
ATE455554T1 (de) 2010-02-15
ATE259243T1 (de) 2004-02-15
DE69631544T2 (de) 2004-12-23
MX9803992A (es) 1998-09-30

Similar Documents

Publication Publication Date Title
ZA969605B (en) Methods for increasing lean tissue mass using ob protein compositions
IL189629A0 (en) Compositions containing human ctla-4 antibodies
RO117177B1 (ro) Proteine recombinante, anti-obezitate, murine şi umane, secvenţă adn, care le codifică, procedeu de producere a proteinei şi conjugat cu acestea
IE893270L (en) Ophthalmic staple and instruments for implementing use
AU6215690A (en) Living tissue equivalents
BE2013C033I2 (fr)
UA43348C2 (uk) Водна фармацевтична композиція, що включає фактор росту нерва (варіанти) та ліофілізований фармацевтичний склад
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
MXPA05004225A (es) Anticuerpos de neutralizacion contra gdf-8, y sus usos.
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
EP0833912A4 (fr) Nouvelle cytokine de type facteur de croissance transformant tgf-beta
ZA965565B (en) Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits.
ZA976181B (en) Methods of enhancing lean tissue mass and bone mineral content and compositions therefor.
ES2191298T3 (es) Cuerpo de implantes.
HK1055255A1 (en) Implant comprising immunologically isolated stromal cells and its use
DE69831223D1 (de) Gefriergetrocknete zusammensetzung des menschlichen,morphogenen knochenproteins mp52
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
AU5569600A (en) Novel protein and dna thereof
AU6860294A (en) New chondrocyte proteins
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
AU3703795A (en) Chondrocyte cell-lines
MD899G2 (ro) Procedeu de activizare a osteogenezei reparatorii
WO1999046381A3 (fr) Gene du fgf humain et produit d'expression genique
AU2003201360A1 (en) Methods of Reducing or Maintaining Reduced Levels of Blood Lipids Using OB Protein Compositions
ZA985233B (en) Improved process for preparing biocompatible surfaces particularly on medical instruments and implants

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees